Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-810 for Impulsive Aggression in Pediatric ADHD
NCT02618408Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jan 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of molindone in intermittent explosive disorder (IED) (3 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Frequency of Impulsive Aggression at 7 weeks. Started Jan 2016; status: completed.
02
Drugs
molindone
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT02618408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618408.